Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oralgen Birch Pollen
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Oralgen Birch Pollen is a sublingual allergen immunotherapy (SLIT) product developed by Artu Biologicals Europe B.V. for the treatment of birch pollen-related allergic rhinoconjunctivitis (hay fever). It is a biologic allergen extract containing standardized birch pollen allergens, with the major allergen Bet v 1 as its primary active component. Administered under the tongue, the therapy is designed to desensitize the immune system and modulate the aberrant IgE-mediated allergic response to birch pollen. The product has been evaluated in a Phase I/IIa dose-escalation trial to assess its safety and tolerability in adults, but it remains an investigational compound without current regulatory approval.
- Brand names
- Oralgen Birch Pollen
02
Targets
Bet v 1Birch pollen allergen-specific immunoglobulin EBirch pollen allergen-specific B-cell receptorBirch pollen allergen peptide–MHC class II complex
Beyond the preview
Go deeper on Oralgen Birch Pollen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oralgen Birch Pollen.